Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edaravone dexborneol for post-stroke cognitive impairment
NCT06315231Phase 2Recruiting
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Apr 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of edaravone dexborneol in post-stroke cognitive impairment (PSCI), sponsored by Simcere Pharmaceutical Group. Started Apr 2024; status: recruiting.
02
Drugs
edaravone dexborneol
03
Conditions
post-stroke cognitive impairment (PSCI)
Beyond the preview
Go deeper on NCT06315231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06315231.